ライフサイエンスコーパス: fenoldopam

1 port, neutralizing the natriuretic effect of fenoldopam.

2 Group 1 received intravenous fenoldopam 0.1 microg/kg/min started at surgical inducti

3 ured during three fixed, escalating doses of fenoldopam (0.03, 0.1, and 0.3 Lg/kg/min) on both a high

4 drated and randomized to receive intravenous fenoldopam (0.05 microg/kg/min titrated to 0.10 microg/k

5 eline or oliguria for >/=6 hours) to receive fenoldopam (338 patients) or placebo (329 patients).

6 ably transfected with rat D1A receptor cDNA, fenoldopam, a D1 agonist, increased phosphatidylinositol

7 fore, during, and after a 3-hour infusion of fenoldopam, a D1-like receptor agonist, with and without

8 Fenoldopam, a peripheral D1R agonist that does not penet

9 Fenoldopam also increased PLC-gamma protein in a time-de

10 enoldopam restored the natriuretic effect of fenoldopam and its inhibitory effect on proximal tubule

11 Perioperative fenoldopam and N-acetylcysteine abrogate the early posto

12 Group 3 received both fenoldopam and N-acetylcysteine, and group 4 patients se

13 e, quinidine, xylometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications.

14 1 microM DA or a dopaminergic D(1) agonist, fenoldopam, but not with the dopaminergic D(2) agonist q

15 Thus, on a high NaCl diet fenoldopam causes natriuresis by inhibiting renal proxim

16 Finally, fenoldopam contributed to perioperative hypotension.

17 On the low NaCl diet, fenoldopam decreased renal distal tubule sodium transpor

18 -nine of 338 patients (20%) allocated to the fenoldopam group and 60 of 329 patients (18%) allocated

19 tality at 30 days was 78 of 338 (23%) in the fenoldopam group and 74 of 329 (22%) in the placebo grou

20 tension occurred in 85 (26%) patients in the fenoldopam group and in 49 (15%) patients in the placebo

21 lic blood pressure was slightly lower in the fenoldopam group than in the placebo group: 62.5 + 6.4 v

22 signing future studies exploring the role of fenoldopam in preventing or treating renal failure in pa

23 arly, the specific dopaminergic D(1) agonist fenoldopam increased lung edema clearance, but quinpirol

24 Fenoldopam increased renal blood flow in a dose-dependen

25 In both intact and reserpinized rats, fenoldopam induced significant sniffing.

26 chelerythrine; calphostin C also blocked the fenoldopam-induced increase in PLC activity.

27 The fenoldopam-induced increase in PLC-gamma and activity wa

28 kinase C (PKC) was also involved, since the fenoldopam-induced increase in PLC-gamma protein was blo

29 On the high NaCl diet, fenoldopam-induced natriuresis was associated with the i

30 h acute kidney injury after cardiac surgery, fenoldopam infusion, compared with placebo, did not redu

31 Fenoldopam is a new, selective, dopamine-1 receptor agon

32 the United States were randomized to receive fenoldopam mesylate (n = 157) or placebo (n = 158).

33 The selective dopamine-1 agonist fenoldopam mesylate does not prevent further renal funct

34 Infusion of fenoldopam mesylate increased CWFA in all cases (P < or

35 Fenoldopam mesylate, a specific agonist of the dopamine-

36 dogs during intravenous infusion of ET-1 and fenoldopam mesylate.

37 nt of the flow changes induced with ET-1 and fenoldopam mesylate.

38 Experiments with the selective D1 agonist fenoldopam or D2 agonist quinpirole and experiments with

39 Continuous infusion of fenoldopam or placebo for up to 4 days with a starting d

40 dopamine (DA) D1 receptor agonist SKF 82526 (fenoldopam) or the D2 receptor agonist quinpirole were d

41 In hypertensive patients, fenoldopam rapidly decreases blood pressure, increases r

42 The addition of enalapril to fenoldopam restored the natriuretic effect of fenoldopam

43 Fenoldopam significantly increased renal plasma flow in

44 We sought to determine a dose of fenoldopam that increases renal blood flow without induc

45 red in 33.6% of patients assigned to receive fenoldopam vs 30.1% assigned to receive placebo (relativ

46 ehospitalization (17.6% vs 19.9%, P =.66) in fenoldopam vs placebo randomized patients, respectively.

47 . 592 + 165 mUmin at 0.3 ilg/kg/min (p < .05 fenoldopam vs. placebo at all three doses).

48 None of the effects of fenoldopam were altered by volume status.

49 Fenoldopam, which is FDA (Food and Drug Administration)